Current challenges for the successful treatment and prevention of Alzheimer's disease: Treating the pathologies of the disease to change its clinical course

Alzheimer's and Dementia

Volumn 4, Issue 1 SUPPL. 1, 2008, Pages

  Schenk, Dale ^a  

^a ELAN PHARMACEUTICALS   (United States)

Author keywords

Alzheimer's disease; Treatments

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; NOOTROPIC AGENT; PROTEIN INHIBITOR; TAU PROTEIN;

ALZHEIMER DISEASE; ARTICLE; AWARENESS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DISEASE COURSE; DRUG TARGETING; HUMAN; NEUROFIBRILLARY TANGLE; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN TARGETING; SENILE PLAQUE;

ALZHEIMER DISEASE; BRAIN; CLINICAL TRIALS AS TOPIC; HUMANS;

EID: 38049086649     PISSN: 15525260     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jalz.2007.11.009     Document Type: Article

References (8)

1. Thal L.J. The Alzheimer's Disease Cooperative Study in 2004 (review). Alzheimer Dis Assoc Disord 18 (2004) 183-185
2. Dubois B., Feldman H.H., Jacova C., Dekosky S.T., Barberger-Gateau P., Cummings J., et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria (review). Lancet Neurol 6 (2007) 734-746
3. McKhann G., Drachman D., Folstein M., Katzman R., Price D., and Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34 (1984) 939-944
4. Galasko D., Chang L., Motter R., Clark C.M., Kaye J., Knopman D., Thomas R., et al. High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol 55 (1998) 937-945
5. Fagan A.M., Mintun M.A., Mach R.H., Lee S.Y., Dence C.S., Shah A.R., et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 59 (2006) 512-519
6. Small G.W., Kepe V., Ercoli L.M., Siddarth P., Bookheimer S.Y., Miller K.J., et al. PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med 355 (2006) 2652-2663
7. Gilman S., Koller M., Black R.S., Jenkins L., Griffith S.G., Fox N.C., et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64 (2005) 1553-1562
8. Thal L.J., Black R., Vellas B., Fox N., Daniels M., McLennan G., et al. Long term follow up of patients immunized with AN1792 (QS-21): reduced functional decline in antibody responses. Alzheimer's & Dementia 3 (2007) 196